600176-67-8

Basic information

• Product Name: Thiocyanic acid, 2,3-dihydro-7-hydroxy-1H-inden-4-yl ester (9CI)
• Synonyms: Thiocyanic acid, 2,3-dihydro-7-hydroxy-1H-inden-4-yl ester (9CI)
• CAS NO: 600176-67-8
• Molecular Formula: C₁₀H₉NOS
• Molecular Weight: 191.24956
• Product Categories: CYCLOPENTANE
• Mol File: 600176-67-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Thiocyanic acid, 2,3-dihydro-7-hydroxy-1H-inden-4-yl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Thiocyanic acid, 2,3-dihydro-7-hydroxy-1H-inden-4-yl ester (9CI)(600176-67-8)
• EPA Substance Registry System: Thiocyanic acid, 2,3-dihydro-7-hydroxy-1H-inden-4-yl ester (9CI)(600176-67-8)

Safety Data

• Hazardous Substances Data: 600176-67-8(Hazardous Substances Data)

Upstream product

• 40731-98-4 4-hydroxy-2,3-dihydroindan-1-one 
• 1641-41-4 4-indanol 
• 540-72-7 sodium thiocyanide 

Downstream Products

• 947740-22-9 {7-[2-(3-morpholin-4-yl-prop-1-ynyl)-6-(4-trifluoromethylphenylethynyl)-pyridin-4-ylsulfanyl]-indan-4-yloxy}-acetic acid methyl ester 
• 947740-21-8 {7-[2-bromo-6-(4-trifluoromethyl-phenylethynyl)-pyridin-4-ylsulfanyl]-indan-4-yloxy}-acetic acid methyl ester 

Relevant articles and documents

Design of a partial PPARδ agonist

Structure based ligand design was used in order to design a partial agonist for the PPARδ receptor. The maximum activation in the transactivation assay was reduced from 87% to 39%. The crystal structure of the ligand binding domain of the PPARδ receptor in complex with compound 2 was determined in order to understand the structural changes which gave rise to the decrease in maximum activation.

Compounds that modulate PPAR activity and methods of preparation

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

Compounds that modulate PPAR activity and methods of preparation

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

Compounds that modulate PPAR activity and methods for their preparation

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.